FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug
FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia
The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.